- Home
- CLPR vs ATNM Comparison
CLPR vs ATNM Comparison
Compare CLPR & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- ATNM
- Stock Information
- Founded
- CLPR 2015
- ATNM 2000
- Country
- CLPR United States
- ATNM United States
- Employees
- CLPR N/A
- ATNM N/A
- Industry
- CLPR Real Estate Investment Trusts
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- CLPR Real Estate
- ATNM Health Care
- Exchange
- CLPR Nasdaq
- ATNM Nasdaq
- Market Cap
- CLPR 57.5M
- ATNM 50.2M
- IPO Year
- CLPR 2017
- ATNM N/A
- Fundamental
- Price
- CLPR $3.92
- ATNM N/A
- Analyst Decision
- CLPR
- ATNM Strong Buy
- Analyst Count
- CLPR 0
- ATNM 2
- Target Price
- CLPR N/A
- ATNM $4.50
- AVG Volume (30 Days)
- CLPR 60.1K
- ATNM 108.6K
- Earning Date
- CLPR 10-30-2025
- ATNM 11-13-2025
- Dividend Yield
- CLPR 9.79%
- ATNM N/A
- EPS Growth
- CLPR N/A
- ATNM N/A
- EPS
- CLPR N/A
- ATNM N/A
- Revenue
- CLPR $154,103,000.00
- ATNM N/A
- Revenue This Year
- CLPR N/A
- ATNM N/A
- Revenue Next Year
- CLPR N/A
- ATNM N/A
- P/E Ratio
- CLPR N/A
- ATNM N/A
- Revenue Growth
- CLPR 7.69
- ATNM N/A
- 52 Week Low
- CLPR $3.39
- ATNM $1.03
- 52 Week High
- CLPR $7.12
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- CLPR 45.56
- ATNM 45.01
- Support Level
- CLPR $3.84
- ATNM $1.56
- Resistance Level
- CLPR $4.16
- ATNM $1.64
- Average True Range (ATR)
- CLPR 0.18
- ATNM 0.06
- MACD
- CLPR -0.01
- ATNM -0.00
- Stochastic Oscillator
- CLPR 45.93
- ATNM 23.08
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.